Novartis and MMV reported Phase 3 results for GanLum, a combination of ganaplacide and lumefantrine, showing 97.4% cure rates in acute uncomplicated Plasmodium falciparum malaria versus 94% for the comparator in a large multi‑country trial. The KALUMA study enrolled 1,688 participants across 12 African nations and positions GanLum as a potential tool against emerging artemisinin resistance. Company scientists said the novel imidazolopiperazine ganaplacide targets the parasite secretory pathway, offering a new mechanism to broaden the antimalarial armamentarium. Global health groups and regulators will evaluate rollout, resistance‑management strategies, and manufacturing scale-up for deployment in endemic regions.